LeMaitre Vascular (LMAT) Set to Post Earnings on Wednesday

LeMaitre Vascular (NASDAQ:LMAT) is projected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.6860 per share and revenue of $67.39 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%. The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 EPS. On average, analysts expect LeMaitre Vascular to post $2.89 EPS for the current fiscal year and $3.18 EPS for the next fiscal year.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $80.94 on Monday. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 28.40, a price-to-earnings-growth ratio of 2.33 and a beta of 0.51. LeMaitre Vascular has a 1 year low of $78.22 and a 1 year high of $118.01. The business has a 50-day moving average of $81.20 and a two-hundred day moving average of $94.19. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LMAT shares. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Wells Fargo & Company dropped their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 5th. Finally, Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.